Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

5.310 -0.230 (-4.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 759,233
Open 5.620
Bid (Size) 5.130 (1)
Ask (Size) 5.340 (2)
Prev. Close 5.540
Today's Range 5.280 - 5.660
52wk Range 5.280 - 20.64
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-64.05%
-64.05%
1 Month
-39.24%
-39.24%
3 Month
-36.25%
-36.25%
6 Month
-51.28%
-51.28%
1 Year
-71.99%
-71.99%

More News

Read More
Where Arcutis Biotherapeutics Stands With Analysts
Via Benzinga
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Why Shares of Arcutis Biotherapeutics Fell This Week
Via The Motley Fool
Arcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic Dermatitis
Via Benzinga
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
7 Analysts Have This to Say About Arcutis Biotherapeutics
Via Benzinga
8 Analysts Have This to Say About Arcutis Biotherapeutics
Via Benzinga
US Stocks Mostly Higher; RH Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
3 Biotech Stocks Due for a Massive Short Squeeze
Via InvestorPlace
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
Via Talk Markets
Arcutis Appoints Interim Chief Financial Officer (CFO)
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Report Second Quarter Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.